Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

Inclusion Criteria:

   - Written informed consent is obtained from each patient's parent or legal guardian and
   written assent is obtained from each patient.

   - The patient is a male or female 6 through 17 years of age with a body mass index (BMI)
   equal to or greater than 10th percentile for age and gender, inclusive.

   - The patient has a diagnosis of narcolepsy with cataplexy or narcolepsy without
   cataplexy according to the criteria established by the International Classification of
   Sleep Disorders (ICSD)-2 for narcolepsy.

Exclusion Criteria:

   - The patient has any clinically significant uncontrolled medical condition (treated or
   untreated) other than narcolepsy.

   - The patient has a clinically significant deviation from normal in ECG, physical
   examination or vital sign findings, as determined by the investigator or medical
   monitor.

   - The patient is pregnant or lactating. (Any patient becoming pregnant during the study
   will be withdrawn from the study)

   - The patient has any history of seizures, including febrile seizures, or a family
   history of seizures (in parents or siblings) which is not a consequence of trauma,
   stroke, or metabolic disturbance.

   - The patient has a history of head trauma associated with loss of consciousness.

   - The patient has current suicidal ideation, a history of a suicidal ideation, or a
   history of a suicide attempt.

   - The patient has a history of major depressive disorder, bipolar disorder, other
   significant mood disorders, schizophrenia and other psychotic disorders, eating
   disorders, or has a family history of suicide.

   - The patient has left ventricular hypertrophy or the patient has mitral valve prolapse
   and has experienced mitral valve prolapse syndrome.

   - The patient has received any investigational drug within 30 days or 5 half-lives
   (whichever is longer) before the 1st dose of study drug, or in the case of a new
   chemical entity, 3 months or 5 half-lives (whichever is longer) before the 1st dose of
   study drug.

      - The patient has used any monoamine oxidase inhibitors (MAOIs) or stimulants
      within 14 days or 5 half-lives (whichever is longer) of the baseline visit.

      - The patient has used modafinil or armodafinil within 4 weeks of the baseline
      visit.

      - The patient has used an inducer of CYP3A4/5 within 28 days prior to study drug
      administration.

      - The patient has used an inhibitor of CYP3A4/5 within 14 days or 5 half lives
      (whichever is longer) prior to study drug administration.

      - The patient has a known sensitivity or idiosyncratic reaction to any compound
      present in modafinil or armodafinil, their related compounds, or to any
      metabolites or compound listed as being present in these medications.

      - The patient has a history of any clinically significant cutaneous drug reaction,
      or a history of clinically significant hypersensitivity reaction, including
      multiple allergies or drug reactions

      - Other criteria apply, please contact the investigator for additional information